Awasthi Atul, Razzak Majid, Al-Kassas Raida, Harvey Joanne, Garg Sanjay
School of Pharmacy, The University of Auckland, Auckland, New Zealand.
Profiles Drug Subst Excip Relat Methodol. 2013;38:315-66. doi: 10.1016/B978-0-12-407691-4.00007-1.
Moxidectin or F28249α is a potent endectocide and semisynthetic methoxime derivative of naturally occurring nemadectin. It is well known for the novel mode of action against a broad range of nematode and anthropod animal parasites. In this work, physicochemical and pharmaceutical aspects of moxidectin are described including stability, semisynthesis, purification processes, formulation compositions, impurities, and degradation pathways. Additional experiments such as DSC, XRD, and CHN analysis were carried out to complete the profile of moxidectin. The importance of safety and quality of drug substances was highlighted by chronological developments involving moxidectin and its analogues. The information gathered from the literature was used to trace the origins of moxidectin-related substances presented in the European Pharmacopeia (EP) compendial monograph. During the review, it was noticed that majority of impurities presented in the EP does not have any potential to increase with time in drug substance or formulated products; therefore, they do not require monitoring during stability studies. This also showed the requirement for further characterization of the impurities observed during long-term storage and development of stability indicating methods distinguishing between process impurities and the true degradation products. Furthermore, the stability of moxidectin in formulations is also reviewed in conjunction with known degradation routes and innovative ways to formulate products that are stable and effective at intended shelf life.
莫西菌素或F28249α是一种强效的体内外寄生虫杀虫剂,是天然存在的奈马克丁的半合成甲氧肟衍生物。它以对多种线虫和节肢动物寄生虫具有新颖的作用方式而闻名。在这项工作中,描述了莫西菌素的物理化学和药学方面,包括稳定性、半合成、纯化过程、制剂组成、杂质和降解途径。还进行了差示扫描量热法(DSC)、X射线衍射(XRD)和元素分析(CHN分析)等额外实验,以完善莫西菌素的概况。莫西菌素及其类似物的时间发展突出了原料药安全性和质量的重要性。从文献中收集的信息用于追溯欧洲药典(EP)各论专论中出现的与莫西菌素相关物质的来源。在审查过程中,注意到EP中呈现的大多数杂质在原料药或制剂产品中没有随时间增加的任何可能性;因此,在稳定性研究期间不需要对其进行监测。这也表明需要进一步表征在长期储存期间观察到的杂质,并开发能够区分工艺杂质和真正降解产物的稳定性指示方法。此外,还结合已知的降解途径以及在预期保质期内稳定且有效的制剂创新方法,对莫西菌素在制剂中的稳定性进行了综述。